Clinical and laboratory practice for lupus anticoagulant testing : an International Society of Thrombosis and Haemostasis Scientific and Standardization Committee survey by Cohen, Hannah et al.
J Thromb Haemost. 2019;17:1715–1732.	 wileyonlinelibrary.com/journal/jth	 	 | 	1715© 2019 International Society on Thrombosis and 
Haemostasis
 
Received:	16	April	2019  |  Accepted:	28	June	2019
DOI: 10.1111/jth.14560  
O R I G I N A L  A R T I C L E
Clinical and laboratory practice for lupus anticoagulant testing: 
An International Society of Thrombosis and Haemostasis 
Scientific and Standardization Committee survey
Hannah Cohen1,2 |   Ian J. Mackie1 |   Katrien M. J. Devreese3  |   on behalf of the 
International Society for Thrombosis and Haemostasis Scientific and Standardization 
Committee for Lupus Anticoagulant/Antiphospholipid Antibodies
Manuscript handled by: Marc Carrier 
Final	decision:	Marc	Carrier,	28	June	2019	
1Haemostasis Research Unit, Department 
of Haematology, University College London, 
London, UK
2Department of Haematology, University 
College London Hospitals NHS Foundation 
Trust, London, UK
3Coagulation Laboratory, Department of 
Diagnostic Sciences, Ghent University 
Hospital, Ghent, Belgium
Correspondence
Hannah Cohen, Haemostasis Research Unit, 
Department of Haematology, University 
College London, 1st Floor, 51 Chenies 
Mews, WC1E 6HX London, UK.
Email: hannah.cohen@ucl.ac.uk
Abstract
Background: Current guidelines have contributed to more uniformity in the perfor‐
mance and interpretation of lupus anticoagulant (LA) testing. However, points to re‐
consider include testing for LA in patients on anticoagulation, cut‐off values, and 
interpretation of results.
Objectives: The aim of this International Society of Thrombosis and Haemostasis 
Scientific and Standardization committee (ISTH SSC) questionnaire was to capture 
the spectrum of clinical and laboratory practice in LA detection, focusing on variability 
in practice, so that the responses could inform further ISTH SSC recommendations.
Methods: Members of the ISTH SSC on Lupus Anticoagulant/Antiphospholipid 
Antibodies and participants of the Lupus Anticoagulant/Antiphospholipid Antibodies 
Programme of the External quality Control of diagnostic Assays and Tests Foundation 
were invited to complete a questionnaire on LA testing that was placed on the ISTH 
website using RedCap, with data tallied using simple descriptive statistics.
Results: There was good agreement on several key recommendations in the ISTH and 
other guidelines on LA testing, such as sample processing, principles of testing, choice 
of tests, repeat testing to confirm persistent positivity and the use of interpretative 
reporting. However, the results highlight that there is less agreement on some other 
aspects, including the timing of testing in relation to thrombosis or pregnancy, testing in 
patients on anticoagulation, cut‐off values, and calculation and interpretation of results.
Conclusions: Although some of the variability in practice in LA testing reflects the 
lack of substantive data to underpin evidence‐based recommendations, a more uni‐
form approach, based on further guidance, should reduce the inter‐center variability 
of LA testing.
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anticoagulation, antiphospholipid antibodies, confirmatory testing, cut‐off values, lupus 
anticoagulant, pre‐analytical
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1  | INTRODUC TION
Accurate diagnosis of antiphospholipid syndrome (APS) is essential to 
guide appropriate management with the aim of preventing the del‐
eterious consequences of this acquired autoimmune disorder, char‐
acterized by thrombosis (arterial, venous, or microvascular) and/or 
obstetric morbidity in association with persistently positive antiphos‐
pholipid antibodies (aPL). The laboratory diagnostic criteria for aPL 
positivity comprise lupus anticoagulant (LA), IgG and/or IgM anticar‐
diolipin (aCL), and/or anti‐beta 2 glycoprotein I antibodies (aβ2GPI).1 
Identification of aPL positivity strengthens the decision for indefinite 
anticoagulation after a first unprovoked venous thromboembolism 
(VTE) or even after provoked VTE, particularly if the provoking factor 
for VTE appears to be disproportionately mild. It may also affect the 
type of oral anticoagulant that is prescribed.2‒5 In addition, it identifies 
women who require higher than standard prophylactic‐dose antico‐
agulation with low molecular weight heparin (LMWH) during preg‐
nancy,6‒8 and who also require low‐dose aspirin and monitoring for 
placental insufficiency,9 the latter to guide optimal timing of delivery, 
reducing the risk of perinatal morbidity and mortality. Approximately 
50% of APS patients have LA alone,10 with LA detection therefore 
critical for APS diagnosis in these patients. LA is thought to carry the 
highest risk for thrombosis among all aPL11 and the occurrence of a 
thrombotic event may be associated with higher mortality in patients 
with LA.12 LA has been reported to be the primary predictor of ad‐
verse pregnancy outcome in patients with aPL‐associated pregnan‐
cies.13 Detection of LA also enables diagnosis of triple‐aPL‐positive 
patients, who are perceived to be the APS patients at highest risk of 
thrombosis,14,15 and thus, identification of LA enables risk stratifica‐
tion as well as appropriate management of APS patients.
External quality assessment studies on LA testing in Europe have 
shown considerable inter‐laboratory variability, particularly in sam‐
ples with “weak” LA, with false negative and false positive rates of 
10%‐20%.16,17 North American studies have shown false‐negative 
LA	rates	up	to	28%	and	false‐positive	rates	of	around	11%,	whereas	
Australasian studies reported false‐negative rates up to 50% and 
false‐positive LA rates of about 10%.18,19 The discrepancies appear 
to be due to a variety of pre‐ and postanalytical factors as well as 
performance of the tests. There are many differences between labo‐
ratories in the selection of LA tests, source of reagents, methodolog‐
ical detail, and results.18‒24
The 2009 International Society of Thrombosis and Haemostasis 
Scientific and Standardization Committee (ISTH SSC) guidelines on LA 
detection,25 as well as the British Society for Haematology (BSH)26 and 
Clinical and Laboratory Standards Institute (CLSI) guidelines,27 have 
contributed to more uniformity in the performance and interpretation 
of LA testing. However, points to reconsider include testing for LA in 
patients on anticoagulation, cut‐off values and interpretation of results. 
The aim of this ISTH SSC questionnaire was to capture the spectrum of 
clinical and laboratory practice in LA diagnosis, with particular focus on 
issues where there is variability in practice, so that the responses could 
help to inform the formulation of further ISTH SSC recommendations.
2  | METHODS
2.1 | Survey questionnaire
A survey questionnaire (Appendix 1) was formulated and respond‐
ents were requested to provide their opinions on LA testing. The 
questionnaire was placed on the ISTH website using RedCap and 
all members registered on the ISTH SSC for Lupus Anticoagulant/
Antiphospholipid Antibodies on the ISTH website, who are work‐
ers in the field of aPL, were invited by email to participate (n = 479). 
Additionally, participants of the “Lupus Program” external quality ex‐
ercises of the ECAT Foundation (n = 575) were asked to fill out the 
questionnaire.
2.2 | Data analysis
The specific details of returned information were entered onto an 
Excel spreadsheet that included all records and fields, and data tal‐
lied (after the survey deadline) using simple descriptive statistics.
3  | RESULTS
3.1 | General information
One‐hundred and eighty‐five responses to the survey were re‐
ceived.	 The	 majority	 (58%)	 were	 from	 laboratory	 scientists,	 with	
hematologists making up 22%. Their views likely represented their 
laboratories’ policies. Almost three‐quarters (73%) of respondents 
worked in hospital laboratories, approximately 50% of whom were 
in university hospital laboratories. As regards the volume of samples 
tested, 59.1% of laboratories undertake between 500 to 4000 LA 
tests annually, with 5% of laboratories undertaking more than 6000 
and	2.8%	more	than	10	000	LA	tests	annually.
3.2 | Pre‐analytical factors
Timing of LA testing in relation to thrombotic events: the responses 
to the questionnaire showed little agreement on the timing of test‐
ing in relation to a thrombotic event. The most frequent responses 
were to test any time after a thrombotic event (37.6%; but 79%‐54 
Essentials
• Current guidelines have contributed to more uniformity 
in lupus anticoagulant (LA) testing.
• An international survey of clinical and laboratory prac‐
tice in LA testing has been performed.
• Uncertainty on testing in thrombosis, pregnancy, antico‐
agulation, and interpretation of results.
• A more uniform approach should reduce the inter‐center 
variability of LA testing.
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of	these	68	respondents‐were	laboratory	based	and	probably	not	in	
a position to refuse to test), whereas 33.7% stated that the timing 
depended	on	the	clinical	situation,	with	13.8%	stating	that	they	did	
not know or were uncertain.
Timing of LA testing in relation to pregnancy: the questionnaire 
asked for views on the timing of LA testing in relation to pregnancy 
(excluding considerations in relation to the effect of anticoagula‐
tion on LA detection, which are covered below). The majority (60%) 
stated that LA testing could be done at any time in relation to preg‐
nancy, with 20% indicating that LA testing should be deferred for at 
least 6 weeks after pregnancy. Here, 16.7% stated that they did not 
know or were uncertain.
Sample processing:	86.8%	agreed	that	samples	for	LA	should	be	
collected and processed in line with the 2009 guidelines (i.e., blood 
samples collected into 0.105‐0.109 mol/L sodium citrate 9:1, should 
be double centrifuged at 2000 g for 15 minutes at room tempera‐
ture to achieve a residual platelet count of <109/L.)25 51.1% indi‐
cated plasma for LA testing should ideally be frozen within 4 hours, 
although	 30.8%	 thought	 that	 the	 plasma	 should	 ideally	 be	 frozen	
within 2 hours of collection.
Restriction of LA testing because of sample issues: 53.9% stated 
that they would restrict testing if the sample is hemolyzed, with 
29.1%	 and	 18%	 stating	 that	 they	would	 restrict	 LA	 testing	 if	 the	
sample is lipemic or icteric, respectively. Of the former, 37% would 
reject any sample with visible hemolysis, but 33% set limits based 
on plasma hemoglobin concentration, analyser hemolysis/icterus/
lipemia (HIL) flags or subjective scores. Some stated that they would 
restrict photometric based analyzer testing but perform mechan‐
ical end‐point clotting methods in the case of lipemia or icterus, 
whereas 47% and 67% (for lipemia and icterus respectively) stated 
that they would use analyser HIL flags or subjective scoring in de‐
cision making.
3.3 | Testing for LA
Coagulation screen:	83.5%	would	do	coagulation	screening	tests	(pro‐
thrombin time [PT], activated partial thromboplastin time [APTT], 
thrombin time [TT], and/or fibrinogen assay) to provide background 
information about unexpected coagulopathies and undocumented 
anticoagulation.
LA testing: the overwhelming majority (94.5%) agreed that LA 
testing should include two phospholipid‐dependent clotting tests, 
based on different principles, with LA considered positive if one of 
the two tests gives a positive result. The dilute Russell's viper venom 
time	 (DRVVT)	 (98.9%)	 and	 APTT	 using	 a	 reagent	with	 proven	 LA	
sensitivity (79.7%) were used for LA detection by the majority of 
respondents.
LA mixing test and interpretation:	 84.1%	 agreed	 that	 a	 mixing	
test should be performed, using pooled normal plasma (PNP) at a 
patient:PNP ratio of 1:1. Options suggested for the ideal PNP were: 
a commercial PNP that has been platelet depleted at collection and 
is	suitable	for	LA	testing	(47.5%),	prepared	in‐house	PNP	(13.8%),	or	
that either commercial or PNP are suitable (32.0%).
Confirmatory test for LA and order of testing: there were various 
views on when a confirmatory test for LA should be performed, with 
54.9% stating that a confirmatory test should be done only when 
the LA screening test is prolonged; and other views that confirma‐
tory testing should be undertaken on all samples being tested for LA 
(17.6%) or only when the screening and mixing tests are prolonged 
(25.3%) (Figure 1A). With regard to the order of testing, 69.1% agreed 
that the components of LA tests should be performed in a specific 
order, but there was less agreement as to what the order should be, 
with the majority (56.5%) stating the order should be Screen, Mix, 
F I G U R E  1   Responses to questions about performance of lupus 
anticoagulant (LA) tests. (A) When should a confirmatory test 
for	LA	be	performed?	(182	respondents).	(B)	If	you	think	that	it	is	
important to perform the components of the LA test in a specific 
order, what should it be? (124 respondents)
Only when screening test prolonged
On all samples tested for LAC
Only when screening and mixing tests prolonged
Don't know or uncertain
55%
25%
18%
2%
Screen, Mix, Confirm
Screen, Confirm, Mix
All 3 run at the same time
Don't know or uncertain
56.5%
35.5%
5%
3%
A
B
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Confirm, and 35.5% stating that it should be Screen, Confirm, Mix 
(Figure 1B).
Interpretative report on LA result: there was almost universal 
agreement (97.3%) that an interpretative report should be provided 
on the LA result.
3.4 | LA testing in patients on anticoagulants
LA testing in patients on vitamin K antagonists (VKAs): only 41.7% in‐
dicated that it would be appropriate to do LA testing in patients on 
VKAs,	with	52.8%	stating	that	it	would	not	be	appropriate.	Among	
the former group, 36.5% stated that blood samples for LA testing 
should be taken before starting the VKA, 9.5% that they would wait 
for at least 7 days after stopping the VKA and 50% applied other cri‐
teria (which mostly included using tests unaffected by VKA; testing 
depending on the International Normalized Ratio (INR) value; using 
a mixture of patient plasma and PNP; and one participant suggested 
using adapted cut‐off values).
There were also various opinions about selecting samples based 
on the INR range, the commonest responses being that if the INR was 
<1.5, LA could be tested on undiluted plasma (41.9%); if the INR was 
1.5‐3.0, a DRVVT (34.3%) or silica clotting time/APTT (16.9%) could 
be used on a 1:1 patient:PNP mixture. Some respondents (13.4%) 
would test on equal volume mixtures of plasma regardless of INR up 
to	an	INR	of	8.0	(Figure	2A).	Alternative	tests	such	as	Taipan/Ecarin	
Venom time (TVT/ECT) are not commonly used (7%).
LA testing in patients on LMWH or unfractionated heparin (UFH): 
there were a variety of opinions about whether and when to test in 
such patients: not to test patients on LMWH/UFH (33.5%); test for 
LA	during	the	trough	period	(i.e.,	at	least	18	hours	after	the	last	dose)	
on therapeutic LMWH (32.4%) or prophylactic LMWH (27.5%); or to 
test	 on	prophylactic,	 but	 not	 therapeutic	 LMWH	or	UFH	 (25.8%).	
Approximately 10% did not know or were uncertain as to whether or 
when to test for LA in individuals on LMWH or UFH.
There were also differences in opinion about verification of the 
plasma heparin level in relation to the dose, to ensure that the LA 
method is unaffected by anticoagulation: 42.2% stated that an anti‐
Xa assay should be performed for LMWH regardless of whether the 
patient received therapeutic or prophylactic dose, whereas 15.7% 
would test for therapeutic dosing only. There was less confidence 
about dealing with UFH: 21.1% would perform an APTT or anti‐fac‐
tor Xa assay regardless of type of dose and 10.2% would test for 
therapeutic dosed patients only; 33% stated that they did not know 
or were uncertain about the appropriate action in patients receiving 
LMWH or UFH (Figure 2B).
LA testing in patients on direct oral anticoagulants (DOACs): 
70.3% stated that LA testing should not be undertaken in patients 
F I G U R E  2   Responses to questions about performance of lupus 
anticoagulant (LA) tests in patients on anticoagulants. (A) If doing 
LA	tests	in	patients	on	VKAs	(218	respondents).	(B)	If	doing	LA	
tests in patients on LMWH or UFH (202 respondents). (C) If doing 
tests	in	patients	on	DOACs	(180	respondents)33%
27%
13%
11%
6%
3% 8%
35%
8%
17%
27%
13%
31%
8%
18%
43%
INR <1.5, test on undiluted plasma
INR 1.5–<3.0, 1:1 patient:PNP-DRVVT
INR 1.5–<3.0, 1:1 patient:PNP-SCT/aPTT
1:1 patient:PNP unless INR >8.0
DRVVT 1:1 patient:PNP+TVT/ECT ratio
Different criteria to those above
Don't know or uncertain
Anti-Xa for LMWH-therapeutic dose
Anti-Xa for LMWH-therapeutic or prophylactic dose
APTTr or anti-Xa for UFH-therapeutic dose
APTTr or anti-Xa for UFH-therapeutic or prophylactic dose
Don't know or uncertain
FXa inhibitors:test intrough by DRVVT & specific DOAC assay
TVT/ECT suitable for Xa inhibitors
State test you would do for dabigatran
Don't know or uncertain
A
B
c
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on DOACs. There were various suggestions about pre‐analytical 
strategies such as testing during the trough period (17%) or after 
pre‐treatment of the sample with commercial adsorbent or antidote 
preparations (11%). A small proportion (2.7%) stated that LA testing 
may be undertaken in some circumstances in patients on DOACs 
during the peak period.
There were also various suggestions about which tests to do, 
both for factor Xa (FXa) inhibitors and dabigatran. For patients 
receiving FXa inhibitors, 35% would use the DRVVT during the 
trough period and undertake a specific DOAC assay. However, al‐
most half the respondents (49.4%) stated they did not know or 
were uncertain about how to test for LA in patients on DOACs 
(Figure 2C).
3.5 | Cut‐off values and calculations for LA tests
Plasma for normalization of clotting times: there was little agreement 
on the ideal plasma for the calculation of normalized ratios, as shown 
in Figure 3A.
Number of healthy adult donors for the preparation of in‐house 
pooled PNP used for the calculation of normalized ratios: 29.7% stated 
that at least six healthy adult donors should be used, whereas 55.7% 
stated that the number of donors should be at least 40% and 14.6%, 
that a larger number of donors should be used (Figure 3B).
Derivation of normalization of clotting times: 65.7% of respondents 
stated that the denominator to derive normalization of clotting times 
should be PNP analyzed in the same run and 19.4% that the denom‐
inator should be the mean of the reference interval; 11.4% stated 
that they did not know or were uncertain.
Cut‐offs for screen, mixing, and confirmatory tests based on testing 
on plasmas from healthy donors: 50% stated that the cut‐off should 
be the value above the 99th centile of the distribution, 33.9% stated 
that the cut‐off value should be above the 97.5th centile, and 10.6% 
did not know or were uncertain (Figure 4A).
In‐house	 cut‐off	 values	 were	 calculated	 by	 78.9%	 of	 respon‐
dents’	 laboratories.	More	than	one‐half	 (58.1%)	stated	that	cut‐off	
values could be based on 60‐120 healthy donors, with the remain‐
der of views on the number of donors for cut‐off values ranging be‐
tween <20 and 120, with 14.0% stating that they did not know or 
were uncertain (Figure 4B). Among those who indicated to use the 
99th centile, only 12% indicated to use >120 healthy donors to do 
so, 13% indicated to use 60‐120 healthy volunteers and the majority 
(56%) indicated to use 20‐60 healthy donors. Reasons given to not 
calculate in‐house cut‐off values were that it is too laborious, the 
high cost and lack of availability of healthy donors.
Confirmation of manufacturer cut‐off values for LA positivity by local 
validation:	 81.2%	 agreed	 that	 this	 should	 be	 undertaken,	whereas	
8.8%	did	not	agree,	and	9.9%	did	not	know	or	were	uncertain.
Cut‐off for the percentage correction (if used) based on testing on 
plasma from healthy donors mixed with the PNP at 1:1 proportion: there 
were divided views as to whether the percentage correction should 
be above the 99th or 97.5th centile, with 39.5% stating that this 
should be the value above the 99th centile of the distribution, 31.4% 
above the 97.5th centile, and 24.4% stating that they did not know 
or were uncertain (Figure 5A).
Interpretation of the mixing test: approximately one‐half of the re‐
spondents	(45.8%)	used	a	normalized	clotting	time,	with	17.5%	using	
F I G U R E  3   Responses to questions about normalized ratios. 
(A) Which type of plasma should be used for normalization? (191 
respondents). (B) If in‐house PNP is used for normalization, how 
many	donors	should	be	used	for	the	pool?	(158	respondents)
Commercial PNP
In-house PNP
Either commercial or in-house PNP
Commercial LAC-ve control plasma
Don't know or uncertain
38%
15%
32%
6%
9%
6 healthy adult donors
40 healthy adult donors
A larger number of adult donors
30%
15%
56%
≤
≤
A
B
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the Rosner index (index of circulating anticoagulant), both Rosner 
index and normalized clotting time (15.3%) and 12.4% stating that 
they did not know or were uncertain (Figure 5B).
Confirmation of persistent LA positivity:	88.8%	stated	that	a	first	
LA should be confirmed to be persistently positive on a second sam‐
ple after 12 weeks.
F I G U R E  4   Responses to questions about cut‐off values. (A) 
What should the values be for screen, mixing, and confirmation 
tests, derived from tests on plasmas from healthy donors? 
(180	respondents).	(B)	In‐house	cut‐off	values	(centiles)	should	
be calculated using how many healthy donor plasmas? (179 
respondents)
Value above 99th centile
Value above 97.5th centile
Other
Don't know or uncertain
50%
34%
6%
11%
<20 donors
20-60 donors
60-120 donors
>120 donors
Other
Don't know or uncertain
58%
13%
7%
4%
14%
4%
A
B
F I G U R E  5   Responses to questions about percentage correction 
and interpretation. (A) What should be the cut‐off for percentage 
correction, when testing plasmas from healthy donors mixed 1:1 
with PNP? (172 respondents). (B) How do you interpret the mixing 
test? (177 respondents)
Value above 99th centile
Value above 97.5th centile
Other
Don't know or uncertain
40%
31%
5%
24%
Rosner index
Normalized clotting time
Rosner index and normalized clotting time
Other
Don't know or uncertain
18%
46%
15%
9%
12%
A
B
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4  | DISCUSSION
The results of this ISTH SSC survey are encouraging as they show 
good agreement on several key recommendations in the current 
ISTH and other guidelines on LA testing,25‒27 such as sample pro‐
cessing, principles of testing, choice of tests, repeat testing to con‐
firm persistent positivity, and the use of interpretative reporting. 
However, they highlight that there is less agreement on some other 
aspects of LA testing, including the timing of testing in relation to 
thrombosis or pregnancy, testing in patients on anticoagulation, cut‐
off values, and calculation and interpretation of results. Although 
some of the variability in practice reflects the lack of substantive 
data to underpin evidence‐based recommendations, a more uni‐
form approach in many aspects of LA testing should be feasible and 
would reduce the inter‐center variability in LA test results.
Notably, the responses to the survey showed little agreement 
on the timing of testing in relation to a thrombotic event. The 
2009 ISTH guideline advises caution in interpretation of LA re‐
sults close to a thromboembolic event because patients may be 
treated with full doses of heparin and/or VKA and furthermore, 
acute‐phase reactants such as FVIII may be increased during acute 
events.25 aPL may fluctuate during pregnancy, and LA test results 
may not be representative during all three trimesters.28‒30 LA test‐
ing may be required during pregnancy, particularly when patients 
with pregnancy morbidity have not been previously investigated 
for aPL. In this situation, LA testing should be undertaken with the 
cognizance that negative aPL during pregnancy does not exclude 
a diagnosis of APS and that testing should be undertaken post‐de‐
livery to establish true aPL status.
The rejection of samples because of hemolysis appeared to be 
common, but lower numbers of respondents rejected samples be‐
cause of lipemia or icterus. Local policies are likely to vary depend‐
ing on the type of analyser used, its end‐point detection system 
and the ability to objectively assess the level of the interfering 
substance.
There is not uniform agreement on LA testing in patients on an‐
ticoagulation with regard to whether to test or not and which meth‐
ods to use, and this is reflected in the variable approaches suggested 
by respondents to the survey. Only 42% indicated that it would be 
appropriate to do LA testing in patients on VKAs, with various opin‐
ions on criteria for timing of blood sampling. Opinions also varied 
about testing at different INR ranges, whether one should do the 
test on mixed plasmas and which tests to do. Although LA testing 
in patients on VKAs is challenging, definition of LA status in pa‐
tients on VKAs could identify APS patients with single aPL positiv‐
ity for LA. The TVT/ECT test for LA may be useful in patients on 
VKA as, unlike Russell Viper venom, Taipan venom directly activates 
prothrombin and is not affected by VKA.31‒33 The TVT/ECT test is 
currently being validated in an ISTH SSC project in APS patients on 
VKAs,34 but appears to have good specificity, although (in nonan‐
ticoagulated patients) it is less sensitive than the DRVVT.35 In APS 
patients on DOAC FXa inhibitors, APTT‐based tests are problematic 
and false‐positive results have been reported with the DRVVT, even 
at trough rivaroxaban levels.36 The TVT/ECT has been shown to be 
unaffected by rivaroxaban.37,38 The use of adsorbent reagents to 
remove DOAC and allow LA testing in the normal way are being ex‐
plored and preliminary results are encouraging.39‒41
There were various views on when a confirmatory test for LA 
should be performed, with 55% of respondents stating that confirma‐
tory testing should only be undertaken when the screening test is pro‐
longed. The majority of respondents (69%) agreed that the components 
of lupus anticoagulant tests should be performed in a specific order, but 
there was less agreement as to what the order should be. The range of 
views probably reflects the variability between individual laboratories 
with regard to how they are set up in terms of analyzers, degree of 
automation, computer systems, and logistics, and these factors should 
be taken into account when making recommendations on LA testing.
There was considerable lack of agreement on the majority of aspects 
related to cut‐off values and calculation and interpretation of results. 
Although 79% stated that they calculate their own in‐house values, 
there were divided views on whether the cut‐off should be the 99th or 
the 97.5th centile. It is important that any recommendation about this 
should have a valid statistical basis.42 Laboratories need to consider 
whether they are calculating an in‐house cut‐off value (in which case at 
least 120 different healthy normal subjects are needed to calculate the 
97.5th centile with 95% confidence) or verifying a manufacturer's cut‐off 
(when 20‐40 normal subjects may be used).43‒45 From a statistical point 
of view, the minimum sample size for a reliable estimation of the 99th 
centile is at least 300.42,46 The poor agreement on the number of donors 
needed to calculate the cut‐off is probably determined by the local avail‐
ability and costs rather than strong views about what should be done.
In conclusion, the good agreement on several key recommenda‐
tions in the current ISTH and other guidelines on LA testing,25‒27 
such as sample processing, principles of testing, choice of tests, re‐
peat testing to confirm persistent positivity, and the use of inter‐
pretative reporting, suggests that that the recommendations on LA 
testing are associated with more uniformity in LA testing between 
different laboratories. The lack of agreement on other aspects of 
LA testing, including the timing of testing in relation to thrombosis 
or pregnancy, testing in patients on anticoagulation, cut‐off values, 
and calculation and interpretation of results, at least in part, reflects 
the lack of substantive data to underpin evidence‐based recom‐
mendations. However, a more uniform approach in these aspects of 
LA testing, based on further guidance that addresses these areas, 
should reduce the inter‐center variability of LA testing. The plan for 
development of this guidance is to aim for the “best fit,” based on 
a current review of literature led by the ISTH SSC, with the mem‐
bers of the ISTH SSC for Lupus Anticoagulant/Antiphospholipid 
Antibodies as a Sounding Board.
ADDENDUM
H. Cohen devised and analyzed the LA survey questionnaire, wrote 
the first draft of the manuscript, and undertook critical revision of 
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the	manuscript.	 K.	M.	 J.	 Devreese	 devised	 the	 questionnaire	 and	
undertook	critical	revision	of	the	manuscript.	I.	J.	Mackie	provided	
critical review of the questionnaire and undertook critical revision 
of the manuscript.
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